Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV

Richetta, Matías; Gómez, Emma Laura Alfaro; Lucero, María Soledad; Zoth, Silvina Andrea Chimeno; Gravisaco, Marí­a José; Calamante, Gabriela; Berinstein, Analía

doi:10.1016/j.vaccine.2016.11.029

Cited by 11 publications

(4 citation statements)

References 41 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mouse monoclonal antibodies have been developed for many years and diverse antibodies have been quickly obtained and applied to virus infection or treatment-related research in animal models[ 20 – 22 ]. The DNA prime-protein boost immunization approach has been shown to generate high affinity monoclonal antibodies[ 23 , 24 ]. In the present study, we employed this strategy to generate monoclonal antibodies against the SARS-CoV-2 spike protein.…”

Section: Introductionmentioning

confidence: 99%

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

et al. 2022

View full text Add to dashboard Cite

Background Calls for the coronavirus to be treated as an endemic illness, such as the flu, are increasing. After achieving high coverage of COVID-19 vaccination, therapeutic drugs have become important for future SARS-CoV-2 variant outbreaks. Although many monoclonal antibodies have been approved for emergency use as treatments for SARS-CoV-2 infection, some monoclonal antibodies are not authorized for variant treatment. Broad-spectrum monoclonal antibodies are unmet medical needs. Methods We used a DNA prime-protein boost approach to generate high-quality monoclonal antibodies. A standard ELISA was employed for the primary screen, and spike protein-human angiotensin-converting enzyme 2 blocking assays were used for the secondary screen. The top 5 blocking clones were selected for further characterization, including binding ability, neutralization potency, and epitope mapping. The therapeutic effects of the best monoclonal antibody against SARS-CoV-2 infection were evaluated in a hamster infection model. Results Several monoclonal antibodies were selected that neutralize different SARS-CoV-2 variants of concern (VOCs). These VOCs include Alpha, Beta, Gamma, Delta, Kappa and Lambda variants. The high neutralizing antibody titers against the Beta variant would be important to treat Beta-like variants. Among these monoclonal antibodies, mAb-S5 displays the best potency in terms of binding affinity and neutralizing capacity. Importantly, mAb-S5 protects animals from SARS-CoV-2 challenge, including the Wuhan strain, D614G, Alpha and Delta variants, although mAb-S5 exhibits decreased neutralization potency against the Delta variant. Furthermore, the identified neutralizing epitopes of monoclonal antibodies are all located in the receptor-binding domain (RBD) of the spike protein but in different regions. Conclusions Our approach generates high-potency monoclonal antibodies against a broad spectrum of VOCs. Multiple monoclonal antibody combinations may be the best strategy to treat future SARS-CoV-2 variant outbreaks.

show abstract

Section: Introductionmentioning

confidence: 99%

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Numerous studies have reported the expression of immunogenic hemagglutinin-neuraminidase (HN) protein of NDV in plants, eliciting specific immune responses in chickens and mice ( Hahn et al., 2007 ; Gómez et al., 2009 ; Ma et al., 2020 ; Shahid et al., 2020 ; Nurzijah et al., 2022 ). Similarly, vaccines for infectious bursal disease virus (IBDV) and the poultry parasite Eimeria have been expressed in plants, demonstrating the potential for plant-based vaccine production ( Richetta et al, 2017 ; Lucero et al, 2019 ; Rage et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

A preliminary study of the immunogenic response of plant-derived multi-epitopic peptide vaccine candidate of Mycoplasma gallisepticum in chickens

Mugunthan,

Venkatesan,

Govindasamy

et al. 2024

Front. Plant Sci.

View full text Add to dashboard Cite

Mycoplasma gallisepticum (MG) is responsible for chronic respiratory disease in avian species, characterized by symptoms like respiratory rales and coughing. Existing vaccines for MG have limited efficacy and require multiple doses. Certain MG cytoadherence proteins (GapA, CrmA, PlpA, and Hlp3) play a crucial role in the pathogen’s respiratory tract colonization and infection. Plant-based proteins and therapeutics have gained attention due to their safety and efficiency. In this study, we designed a 21.4-kDa multi-epitope peptide vaccine (MEPV) using immunogenic segments from cytoadherence proteins. The MEPV’s effectiveness was verified through computational simulations. We then cloned the MEPV, introduced it into the plant expression vector pSiM24-eGFP, and expressed it in Nicotiana benthamiana leaves. The plant-produced MEPV proved to be immunogenic when administered intramuscularly to chickens. It significantly boosted the production of immunoglobulin Y (IgY)-neutralizing antibodies against cytoadherence protein epitopes in immunized chickens compared to that in the control group. This preliminary investigation demonstrates that the plant-derived MEPV is effective in triggering an immune response in chickens. To establish an efficient poultry health management system and ensure the sustainability of the poultry industry, further research is needed to develop avian vaccines using plant biotechnology.

show abstract

“…We have previously demonstrated that VP2 transient expression in N benthamiana represents a viable platform for the production of a safe, economic, and efficacious vaccine against IBD. Our immunogen, consisting of plant protein extract, can both achieve protection against disease when administered im to young chicken and induce uniform long-lasting high titer antibody response in breeder hens in order to provide effective passive immunity to the offspring ( Lucero et al, 2016 , 2019 ; Richetta et al, 2017 ). In the present work, we continued to study the efficacy of the immunogen and demonstrated that it can also elicit a protective immune response when orally administered.…”

Section: Discussionmentioning

confidence: 99%

Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Infectious bursal disease virus (IBDV) is the etiological agent of an immunosuppressive and highly contagious disease that affects young birds causing important economic losses in the poultry industry worldwide. We have previously developed a plant-based vaccine candidate for infectious bursal disease (IBD) that is able to protect against infection with IBDV when administered through intramuscular (im) route. Given that oral vaccination is non-invasive and stimulates the immunity of the mucosal gastrointestinal surface, the initial site of contact and entry of IBDV, the aim of this work was to study if our immunogen was also able to elicit a protective immune response when orally administered. We demonstrated that 85% of the animals that received two oral doses of the vaccine formulation and all animals that were orally boosted after an im prime scheme developed virus neutralizing antibodies and were protected against IBDV infection, evidenced by the bursa/body weight (BB) ratio, absence of T-cell infiltration, and low viral load in bursa. Although mild to moderate bursal damage was observed in some of these animals, these lesions were not as severe as the ones observed in challenged control groups, which also presented signs of acute inflammation, bursal atrophy, T-cell infiltration, and absence of viral clearance. These results show that two immunizations with our recombinant immunogen are able to induce a specific and protective immune response in chicken against IBDV when orally administered in a prime/boost scheme or when the oral boost follows an im prime scheme. In conclusion, our oral plant-based vaccine candidate could represent a viable alternative to conventional vaccines and is of great interest to the poultry industry.

show abstract

Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV

Cited by 11 publications

References 41 publications

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

A preliminary study of the immunogenic response of plant-derived multi-epitopic peptide vaccine candidate of Mycoplasma gallisepticum in chickens

Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease

Contact Info

Product

Resources

About